Pediatric DermatologyEarly View PHOTOQUIZ Pustular eruption in a 16-year-old boy Clément Pruvot MD, Corresponding Author Clément Pruvot MD [email protected] orcid.org/0000-0003-1894-0749 Dermatology Department, Valenciennes Hospital, Valenciennes, France University of Lille, Lille, France Correspondence Clément Pruvot, Service de Dermatologie, Centre Hospitalier de Valenciennes, 114 Avenue Desandrouin, 59300 Valenciennes, France. Email: [email protected]Search for more papers by this authorMaud Fialek MD, Maud Fialek MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorMarie Weinborn MD, Marie Weinborn MD Dermatology Department, Valenciennes Hospital, Valenciennes, France Anatomic Pathology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorCoralie Becquart MD, Coralie Becquart MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorDelphine Deregnaucourt MD, Delphine Deregnaucourt MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorMarlène Vonarx MD, Marlène Vonarx MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this author Clément Pruvot MD, Corresponding Author Clément Pruvot MD [email protected] orcid.org/0000-0003-1894-0749 Dermatology Department, Valenciennes Hospital, Valenciennes, France University of Lille, Lille, France Correspondence Clément Pruvot, Service de Dermatologie, Centre Hospitalier de Valenciennes, 114 Avenue Desandrouin, 59300 Valenciennes, France. Email: [email protected]Search for more papers by this authorMaud Fialek MD, Maud Fialek MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorMarie Weinborn MD, Marie Weinborn MD Dermatology Department, Valenciennes Hospital, Valenciennes, France Anatomic Pathology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorCoralie Becquart MD, Coralie Becquart MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorDelphine Deregnaucourt MD, Delphine Deregnaucourt MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this authorMarlène Vonarx MD, Marlène Vonarx MD Dermatology Department, Valenciennes Hospital, Valenciennes, FranceSearch for more papers by this author First published: 12 February 2024 https://doi.org/10.1111/pde.15563Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol. 1956; 68(12): 385-394. 10.1111/j.1365-2133.1956.tb12774.x CASPubMedWeb of Science®Google Scholar 2Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol. 2008; 33(3): 229-233. 10.1111/j.1365-2230.2008.02706.x CASPubMedWeb of Science®Google Scholar 3Watts PJ, Khachemoune A. Subcorneal pustular dermatosis: a review of 30 years of progress. Am J Clin Dermatol. 2016; 17(6): 653-671. 10.1007/s40257-016-0202-8 PubMedWeb of Science®Google Scholar 4Alhafi MA, Janahi MI, Almossalli ZN. Subcorneal pustular dermatosis in paediatrics: a case report and review of the literature. Cureus. 2021; 13(12):e20221. PubMedGoogle Scholar 5Ingen-Housz-Oro S. Linear IgA bullous dermatosis: a review. Ann Dermatol Venereol. 2011; 138(3): 214-220. 10.1016/j.annder.2011.01.010 CASPubMedWeb of Science®Google Scholar 6Scalvenzi M, Palmisano F, Annunziata MC, Mezza E, Cozzolino I, Costa C. Subcorneal pustular dermatosis in childhood: a case report and review of the literature. Case Rep Dermatol Med. 2013; 2013:424797. PubMedGoogle Scholar 7Kundak S, Bağ Ö, Gülez N, Ergin M. A child with subcorneal pustular dermatosis responded to IVIG treatment (Sneddon-Wilkinson disease). Reumatologia. 2017; 55(6): 323-327. 10.5114/reum.2017.72631 PubMedGoogle Scholar 8Kishimoto M, Komine M, Okada H, et al. Three cases of subcorneal pustular dermatosis with immunohistochemical examinations. J Dermatol. 2023; 50(9): 1150-1155. 10.1111/1346-8138.16850 CASPubMedGoogle Scholar 9Al Ameer A, Al Salman A, Al Braheem I, Al Marzoq Y, Imran M. Subcorneal pustular dermatosis in a 7-year old Saudi child: a case report and review of the literature. J Dermatol Dermatol Surg. 2015; 19(2): 136-139. 10.1016/j.jssdds.2014.01.001 Google Scholar 10Ağladıoğlu Yilmaz S, Bozkay D, Fidan K, Buyan N, SöylemezoĞlu O. The association of sacroiliitis and subcorneal pustular dermatosis in the setting of familial Mediterranean Fever. Gazi Med J. 2008; 19(1): 50-52. Google Scholar 11Yaylı S, Bahadır S, Alpay K, Çimşit G, Reis A. A case of juvenile subcorneal pustular dermatosis successfully treated with acitretin. Int J Dermatol. 2006; 45(9): 1131-1133. 10.1111/j.1365-4632.2006.02984.x PubMedWeb of Science®Google Scholar 12Kasha EE, Epinette WW. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) in association with a monoclonal IgA gammopathy: a report and review of the literature. J Am Acad Dermatol. 1988; 19(5, Pt 1): 854-858. 10.1016/S0190-9622(88)70245-5 PubMedWeb of Science®Google Scholar 13Puechguiral-Renaud I, Carpentier O, Piette F, Delaporte E. Subcorneal pustulosis and Pyoderma gangrenosum associated with a biclonal gammopathy. Eur J Dermatol. 2006; 16(6): 687-690. CASPubMedGoogle Scholar 14Park YK, Park HY, Bang DS, Cho CK. Subcorneal pustular dermatosis treated with phototherapy. Int J Dermatol. 1986; 25(2): 124-126. 10.1111/j.1365-4362.1986.tb04556.x CASPubMedWeb of Science®Google Scholar 15Johnson SA, Cripps DJ. Subcorneal pustular dermatosis in children. Arch Dermatol. 1974; 109(1): 73-77. 10.1001/archderm.1974.01630010049012 CASPubMedGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation

Bullous drug eruptions are infrequent and potentially serious situations. Bullae are characteristic of two main diagnoses: the spectre of toxic epidermal necrolysis (TEN), the most serious, and the bullous fixed drug eruption (FDE); even if other severe drug reactions can sometimes be bullous. The FDE exceptionally occurs as a bullous and generalized form in western countries [1, 2]. Early recognition is necessary because of a potential emergency situation. The distinction between these two entities [...]

Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by anti–tumor necrosis factor-alfa (TNF-α) agents has been described in the literature.1-3 No cases have been reported with ustekinumab. We report a case of BP occurring in a patient treated for 9 months with ustekinumab for severe psoriasis.

To report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86‐year‐old woman presented with bullous pemphigoid after 1 month of treatment with vildagliptin and metformin. After introduction of clobetasol, the symptoms resolved although vildagliptin was continued. However, the skin lesions reappeared 3 months later. Sustained remission was achieved only after definitive withdrawal of vildagliptin. Case 2: A 79‐year‐old man presented with bullous pemphigoid after 37‐month treatment with gliclazide, vildagliptin and metformin. The disease at first responded to clobetasol but 3 months later the lesions reappeared. They finally regressed when the gliptin was discontinued. Case 3: A 77‐year‐old woman, treated with gliclazide and vildagliptin for 26 months, presented with bullous pemphigoid, which responded well to discontinuation of the gliptin and topical clobetasol. Gliptins are new molecules for treatment of type 2 diabetes mellitus, which have been suspected of implication in bullous pemphigoid. Such cases have been described in the literature (seven with vildagliptin and three with sitagliptin). In nine of these cases, the gliptin was associated with metformin, but the latter had never been considered responsible. The mechanism implicated in the development of bullous pemphigoid has not yet been clearly identified, but may involve a modified immune response or alteration of the antigenic properties of the epidermal basement membrane. These reports support the risk of bullous pemphigoid in patients exposed to gliptins.